NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Aquestive Therapeutics Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.
Aquestive Therapeutics is a pharmaceutical company developing medicines through innovative delivery technologies as alternatives to invasive therapies. The company advances epinephrine prodrug candidates, including Anaphylm for severe allergic reactions, and operates PharmFilm, an oral film technology platform. Aquestive manufactures four licensed commercialized products for pharmaceutical companies and maintains facilities in Indiana and New Jersey.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Aquestive Therapeutics Inc stock.
Overvalued: intrinsic value $0.96 per share, market price $3.70, margin of safety -284.6% (as of 2026-11-17).
A 0.6x revenue multiple, discounted for its losses, values the shares at $0.96; the price of $3.70 is 285% above that value.
16 more funds hold it; the full list is part of the paid plan.
All 82 Drug Manufacturers - Specialty & Generic stocks
28 more in this industry show a wider margin of safety.
AQST is overvalued (as of the 2026-11-17 close). A 0.6x revenue multiple, discounted for its losses, values the shares at $0.96; the price of $3.70 is 285% above that value.
$0.96 per share (as of the 2026-11-17 close), against a market price of $3.70. That is a margin of safety of -284.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.